<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=2397&amp;modal=1&amp;valnames=primary_outcome&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="124675" class="table-">
                
                <td>June 22, 2021, 1 a.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum;Intensity of Adverse Events of Special Interest (AESIs) per Investigator&#x27;s Assessment;Intensity of Medically-attended Adverse Events per Investigator&#x27;s Assessment;Intensity of Serious Adverse Events (SAEs) per Investigator&#x27;s Assessment;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events per the Investigator&#x27;s Assessment;Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies;Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Discontinuation;Number of Participants with Death due to a Serious Adverse Event (SAE);Number of Participants with Medically-attended Adverse Events;Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Number of Participants with Unsolicited Adverse Events;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum;Intensity of Adverse Events of Special Interest (AESIs) per Investigator&#x27;s Assessment;Intensity of Medically-attended Adverse Events per Investigator&#x27;s Assessment;Intensity of Serious Adverse Events (SAEs) per Investigator&#x27;s Assessment;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events per the Investigator&#x27;s Assessment;Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies;Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Discontinuation;Number of Participants with Death due to a Serious Adverse Event (SAE);Number of Participants with Medically-attended Adverse Events;Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Number of Participants with Unsolicited Adverse Events;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="78344" class="table-">
                
                <td>Dec. 21, 2020, 12:31 a.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum;Intensity of Adverse Events of Special Interest (AESIs) per Investigator&#x27;s Assessment;Intensity of Medically-attended Adverse Events per Investigator&#x27;s Assessment;Intensity of Serious Adverse Events (SAEs) per Investigator&#x27;s Assessment;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events per the Investigator&#x27;s Assessment;Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies;Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Disctontinuation;Number of Participants with Death due to a Serious Adverse Event (SAE);Number of Participants with Medically-attended Adverse Events;Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Number of Participants with Unsolicited Adverse Events;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum;Intensity of Adverse Events of Special Interest (AESIs) per Investigator&#x27;s Assessment;Intensity of Medically-attended Adverse Events per Investigator&#x27;s Assessment;Intensity of Serious Adverse Events (SAEs) per Investigator&#x27;s Assessment;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events per the Investigator&#x27;s Assessment;Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies;Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Disctontinuation;Number of Participants with Death due to a Serious Adverse Event (SAE);Number of Participants with Medically-attended Adverse Events;Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Number of Participants with Unsolicited Adverse Events;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
June 22, 2021, 1 a.m.	usa	Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum;Intensity of Adverse Events of Special Interest (AESIs) per Investigator's Assessment;Intensity of Medically-attended Adverse Events per Investigator's Assessment;Intensity of Serious Adverse Events (SAEs) per Investigator's Assessment;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events per the Investigator's Assessment;Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies;Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Discontinuation;Number of Participants with Death due to a Serious Adverse Event (SAE);Number of Participants with Medically-attended Adverse Events;Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Number of Participants with Unsolicited Adverse Events;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine	Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum;Intensity of Adverse Events of Special Interest (AESIs) per Investigator's Assessment;Intensity of Medically-attended Adverse Events per Investigator's Assessment;Intensity of Serious Adverse Events (SAEs) per Investigator's Assessment;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events per the Investigator's Assessment;Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies;Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Discontinuation;Number of Participants with Death due to a Serious Adverse Event (SAE);Number of Participants with Medically-attended Adverse Events;Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Number of Participants with Unsolicited Adverse Events;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine
Dec. 21, 2020, 12:31 a.m.	usa	Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum;Intensity of Adverse Events of Special Interest (AESIs) per Investigator's Assessment;Intensity of Medically-attended Adverse Events per Investigator's Assessment;Intensity of Serious Adverse Events (SAEs) per Investigator's Assessment;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events per the Investigator's Assessment;Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies;Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Disctontinuation;Number of Participants with Death due to a Serious Adverse Event (SAE);Number of Participants with Medically-attended Adverse Events;Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Number of Participants with Unsolicited Adverse Events;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine	Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum;Intensity of Adverse Events of Special Interest (AESIs) per Investigator's Assessment;Intensity of Medically-attended Adverse Events per Investigator's Assessment;Intensity of Serious Adverse Events (SAEs) per Investigator's Assessment;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events per the Investigator's Assessment;Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies;Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Disctontinuation;Number of Participants with Death due to a Serious Adverse Event (SAE);Number of Participants with Medically-attended Adverse Events;Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Number of Participants with Unsolicited Adverse Events;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine